Thomas F. Patterson

Dr. Thomas F. Patterson

orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2016 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
TPThomas F. Patterson
Thomas F. Patterson
GTGeorge R. Thompson
George R. Thompson
DDDavid W. Denning
David W. Denning
JFJay A. Fishman
Jay A. Fishman
SHSusan Hadley
Susan Hadley
JBJohn E. Bennett
John E. Bennett
It is important to realize that guidelines cannot always account for individual variation among patients. They are not intended to supplant physician judgment with respect to particular patients or special clinical situations. IDSA considers adherence to these guidelines to be voluntary, with the ultimate determination regarding their application to be made by the physician in the light of each patient's individual circumstances.

1 February 2008 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
TWThomas J. Walsh
Thomas J. Walsh
EAElias J. Anaissie
Elias J. Anaissie
DDDavid W. Denning
David W. Denning
RHRaoul Herbrecht
Raoul Herbrecht
DKDimitrios P. Kontoyiannis
Dimitrios P. Kontoyiannis
TPThomas F. Patterson
Thomas F. Patterson
Aspergillus species have emerged as an important cause of life-threatening infections in immunocompromised patients. This expanding population is composed of pa

1 February 2016 in The Lancet
Verified
Journal Article
Closed access
JMJohan A Maertens
Johan A Maertens
IRIssam I Raad
Issam I Raad
KMKieren A Marr
Kieren A Marr
TPThomas F. Patterson
Thomas F. Patterson
DKDimitrios P Kontoyiannis
Dimitrios P Kontoyiannis
AUAndrew J Ullmann
Andrew J Ullmann

1 June 2021 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
PKPhilipp Koehler
Philipp Koehler
MBMatteo Bassetti
Matteo Bassetti
ACArunaloke Chakrabarti
Arunaloke Chakrabarti
SCSharon Chen
Sharon Chen
Arnaldo L. ColomboArnaldo L. Colombo
Arnaldo L. Colombo
OCOliver A. Cornely
Oliver A. Cornely

1 July 2000 in Medicine
Verified
Journal Article
Closed access
TPThomas F. Patterson
Thomas F. Patterson
WKWilliam R. Kirkpatrick
William R. Kirkpatrick
MWMary White
Mary White
JHJohn W. Hiemenz
John W. Hiemenz
JWJohn R. Wingard
John R. Wingard
JGJohn R. Graybill
John R. Graybill
An abstract is unavailable. This article is available as a PDF only.

22 June 2020 in Intensive Care Medicine
Verified
Journal Article
Open access
PDF file
PVPaul Verweij
Paul Verweij
BRBart Rijnders
Bart Rijnders
RBRoger J. M. Brüggemann
Roger J. M. Brüggemann
EAElie Azoulay
Elie Azoulay
MBMatteo Bassetti
Matteo Bassetti
FVFrank van de Veerdonk
Frank van de Veerdonk
Purpose Invasive pulmonary aspergillosis is increasingly reported in patients with influenza admitted to the intensive care unit (ICU). Classification of patients with influenza-associated pulmonary aspergillosis (IAPA) using the current definitions for invasive fungal diseases has proven difficult, and our aim was to develop case definitions for IAPA that can facilitate clinical studies. Methods A group of 29 international experts reviewed current insights into the epidemiology, diagnosis and management of IAPA and proposed a case definition of IAPA through a process of informal consensus. Results Since IAPA may develop in a wide range of hosts, an entry criterion was proposed and not host factors. The entry criterion was defined as a patient requiring ICU admission for respiratory distress with a positive influenza test temporally related to ICU admission. In addition, proven IAPA required histological evidence of invasive septate hyphae and mycological evidence for Aspergillus. Probable IAPA required the detection of galactomannan or positive Aspergillus culture in bronchoalveolar lavage (BAL) or serum with pulmonary infiltrates or a positive culture in upper respiratory samples with bronchoscopic evidence for tracheobronchitis or cavitating pulmonary infiltrates of recent onset. The IAPA case definitions may be useful to classify patients with COVID-19-associated pulmonary aspergillosis (CAPA), while awaiting further studies that provide more insight into the interaction between Aspergillus and the SARS-CoV-2-infected lung. Conclusion A consensus case definition of IAPA is proposed, which will facilitate research into the epidemiology, diagnosis and management of this emerging acute and severe Aspergillus disease, and may be of use to study CAPA.